Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015718 | 0.88 | LMNA (0.36) | LMNAHSD17B10TDP1 | |
| SCHEMBL531227 | 0.87 | LMNA (0.53) | LMNAHSD17B10TDP1 | |
| SCHEMBL11792381 | 0.85 | HSD17B10 (0.38) | LMNAHSD17B10TDP1 | |
| SCHEMBL15329742 | 0.84 | LMNA (0.33) | LMNAHSD17B10TDP1 | |
| SCHEMBL1277992 | 0.84 | HSD17B10 (0.41) | LMNAHSD17B10TDP1 | |
| SCHEMBL5933519 | 0.84 | LMNA (0.33) | LMNAHSD17B10TDP1 | |
| SCHEMBL4390728 | 0.84 | LMNA (0.33) | LMNAHSD17B10TDP1 | |
| SCHEMBL6374763 | 0.84 | TDP1 (0.34) | LMNAHSD17B10TDP1 | |
| SCHEMBL6122979 | 0.82 | ADRB2 (0.39) | LMNA | |
| SCHEMBL13835928 | 0.82 | CYP3A4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185717-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2016-06-30 | — | — | US | claimed |
| WO-2015000825-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2015-01-08 | — | — | WO | claimed |
| EP-2821394-A1 | Compounds with antibacterial activity | Fundacion MEDINA. Centro de Excelencia en Investigacion de Medicamentos Innovadores en Andalucia (ES) | 2015-01-07 | — | — | EP | claimed |
| US-10414745-B2 | Phenol derivatives to treat cancer | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2019-09-17 | — | — | US | disclosed |
| US-9988417-B2 | Process for the preparation of estetrol | CRYSTAL PHARMA, S.A.U. (ES) | 2018-06-05 | — | — | US | disclosed |
| US-20180148427-A1 | PHENOL DERIVATIVES TO TREAT CANCER | FUNDACION MEDINA CENTRO DE EXCELENCIA DE MEDICAMENTOS INNOVA (ES) | 2018-05-31 | — | — | US | disclosed |
| EP-3288929-A1 | PHENOL DERIVATIVES TO TREAT CANCER | FUNDACIÓN MEDINA. Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía (ES) | 2018-03-07 | — | — | EP | disclosed |
| EP-3046928-B1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA SAU (ES) | 2017-02-08 | — | — | EP | disclosed |
| WO-2016174226-A1 | PHENOL DERIVATIVES TO TREAT CANCER | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2016-11-03 | — | — | WO | disclosed |
| EP-3088396-A1 | PHENOL DERIVATIVES TO TREAT CANCER | FUNDACIÓN MEDINA. Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía (ES) | 2016-11-02 | — | — | EP | disclosed |
| US-20160229885-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-11 | — | — | US | disclosed |
| EP-3046928-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | Crystal Pharma, S.A.U. (ES) | 2016-07-27 | — | — | EP | disclosed |
| US-20160185717-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2016-06-30 | — | — | US | disclosed |
| WO-2015040051-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA, S.A.U. (ES) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015000825-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2015-01-08 | — | — | WO | disclosed |
| EP-2821394-A1 | Compounds with antibacterial activity | Fundacion MEDINA. Centro de Excelencia en Investigacion de Medicamentos Innovadores en Andalucia (ES) | 2015-01-07 | — | — | EP | disclosed |
| WO-2014170295-A1 | COMPOUNDS POTENTIATING THE ACTIVITY OF ANTIFUNGAL DRUGS | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2014-10-23 | — | — | WO | disclosed |
| EP-2792683-A1 | Compounds potentiating the activity of antifungal drugs | Fundacion MEDINA. Centro de Excelencia en Investigacion de Medicamentos Innovadores en Andalucia (ES) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013034780-A2 | PROCESS FOR THE PREPARATION OF ESTETROL AND RELATED COMPOUNDS | CRYSTAL PHARMA, S.A.U. (ES) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414745-B2 | Phenol derivatives to treat cancer | RB1, TP53, NCOR1 | LMNA 3155/4885HSD17B10 2185/4885TDP1 1897/4885 |
| US-20160229885-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | SRD5A2, VKORC1L1, SRD5A1 | LMNA 2098/4885HSD17B10 278/4885TDP1 2823/4885 |
| US-20160185717-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | MRPL21, CFTR, ABCB11 | LMNA 3329/4885HSD17B10 1301/4885TDP1 4210/4885 |
| US-20180148427-A1 | PHENOL DERIVATIVES TO TREAT CANCER | RB1, TP53, NCOR1 | LMNA 3155/4885HSD17B10 2185/4885TDP1 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.